Letrozole Tablets

Letrozole is a new generation aromatase inhibitor, a synthetic benzyltriazole derivative. Letrozole inhibits aromatase, reduces estrogen levels, and thus eliminates the stimulating effect of estrogen on tumor growth. In vitro and in vivo studies have shown that letrozole can effectively inhibit the conversion of androgens to estrogens, and the estrogen of postmenopausal women mainly comes from the aromatization of androgen precursors in peripheral tissues, so it is particularly suitable for postmenopausal breast cancer patients. The in vivo activity of letrozole is 150 to 250 times stronger than that of the first-generation aromatase inhibitor aminoglutethimide. Due to its high selectivity, it does not affect glucocorticoids, mineralocorticoids and thyroid function, and high-dose use has no inhibitory effect on the secretion of adrenal cortical steroids, so it has a high therapeutic index. Various preclinical studies have shown that letrozole has no potential toxicity to systemic systems and target organs, and has the characteristics of good tolerance and strong pharmacological effects. Compared with other aromatase inhibitors and anti-estrogen drugs, letrozole has a stronger anti-tumor effect.

The main ingredient of this product is letrozole.

This product is off-white tablets.

Treatment of postmenopausal women with advanced breast cancer whose estrogen or progesterone receptors are positive or whose receptor status is unknown and who have undergone natural or induced menopause.

The recommended dose of Furlong is 2.5 mg once a day. The time of taking the medicine can be ignored (see Pharmacokinetics-Absorption). Furlong treatment should be continued until the tumor is confirmed to have progressed. Patients with impaired liver function and/or renal function (creatinine clearance ≥10ml/min) do not need to adjust the dose.

Adverse reactions observed in clinical studies were mild to moderate, and it was very rare for treatment to be discontinued due to severe adverse reactions. Many adverse reactions are due to diseases caused by estrogen reduction or normal pharmacological effects (such as hot flashes and thinning hair). Headache, nausea, peripheral edema, fatigue, hot flashes, hair loss, rash, vomiting, indigestion, weight gain, muscle and bone pain, anorexia, vaginal bleeding, increased leucorrhea, constipation, dizziness, increased appetite, sweating, dyspnea, thrombophlebitis, vaginal punctate bleeding, hypertension, and itching.

Hypersensitivity to the active substance and/or any of the excipients; premenopausal women with normal estrogen secretion; pregnancy; lactation.

Precautions for children: Not for children. Precautions for pregnancy and lactation: Animal reproduction studies of letrozole have not been completed. Flon is contraindicated in pregnant and lactating women. Precautions for the elderly: No dosage adjustment is required for elderly patients.

The efficacy of this drug was not improved when it was combined with tamoxifen or other aromatase inhibitors.

Store below 30 degrees.

2.5mg*10s

36 months